N-(4-{2-[5-(Quinolin-3-ylamino)-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-ethyl}-phenyl)-methanesulfonamide | 1104022-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-{2-[5-(Quinolin-3-ylamino)-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-ethyl}-phenyl)-methanesulfonamide
• 英文别名: N-[4-[2-[5-(quinolin-3-ylamino)-3,4-dihydro-1H-2,6-naphthyridin-2-yl]ethyl]phenyl]methanesulfonamide
• CAS: 1104022-48-1
• 化学式: C₂₆H₂₇N₅O₂S
• 分子量: 473.599
• InChiKey: VOBXOFQHLYVTQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  95.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20190161501A1

  公开（公告）日：2019-05-30

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X 1 is each independently CR 4a R 4b , X 2 is each independently CR 4c R 4d , Y 1 and Y 2 are each independently a carbon atom or a nitrogen atom, L is —N(R 6 )—C(═O)— or the like, W is cyclyl or the like, R 2 and R 3 are each independently substituted or unsubstituted alkyl or the like, R 1a , R 1b , R 4a to R 4d , and R 6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供具有D3受体拮抗活性的新化合物。一种由以下式（I）表示的化合物：其中环A是杂环，X1分别是CR4aR4b，X2分别是CR4cR4d，Y1和Y2分别是碳原子或氮原子，L是—N(R6)—C(═O)—或类似物，W是环烷基或类似物，R2和R3分别是取代或未取代的烷基或类似物，R1a、R1b、R4a到R4d和R6分别是氢原子或类似物，p为1或2，q是1到3的整数，n是1到4的整数，s是0到4的整数，或其药学上可接受的盐。
• [EN] COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF<br/>[FR] COMPOSÉS UTILES COMME MODULATEURS DE LA FAAH ET UTILISATION DE CEUX-CI
  申请人：RENOVIS INC

  公开号：WO2009011904A1

  公开（公告）日：2009-01-22

  Compounds are disclosed that have formula (I): where A, B, L1, X, W, Y, R1, R3, and nlare as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, anxiety, depression, inflammation, cognitive disorders, weight and eating disorders, Parkinson's disease, Alzheimer's disease, spasticity, addiction, glaucoma, and others.

  公开了具有通式(I)的化合物：其中A、B、L1、X、W、Y、R1、R3和n1如本文所定义。这些化合物及其药物组合物可用于预防和治疗包括人类在内的哺乳动物的各种病症，包括但不限于疼痛、焦虑、抑郁、炎症、认知障碍、体重和饮食障碍、帕金森病、阿尔茨海默病、痉挛、成瘾、青光眼等。
• Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
  申请人：Shionogi & Co., Ltd.

  公开号：US10870660B2

  公开（公告）日：2020-12-22

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(═O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗活性的新型化合物。 由式（I）代表的化合物： 其中 环 A 是杂环，X1 各自独立地为 CR4aR4b，X2 各自独立地为 CR4cR4d，Y1 和 Y2 各自独立地为碳原子或氮原子、 L是-N(R6)-C(═O)-或类似物，W是环烷基或类似物，R2和R3各自独立地是取代或未取代的烷基或类似物，R1a、R1b、R4a至R4d和R6各自独立地是氢原子或类似物、 p 是 1 或 2，q 是 1 至 3 的整数，n 是 1 至 4 的整数，s 是 0 至 4 的整数、 或其药学上可接受的盐。